Table 1.
Demographics and clinical information of our sample.
| Feature | HC (N=59) |
Escitalopram | Sertraline | Venlafaxine-XR | HC vs. MDD | Treatment | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NR (N=22) |
R (N=21) |
NR vs R | NR (N=19) |
R (N=23) |
NR vs R | NR (N=21) |
R (N=18) |
NR vs R | ||||
| Sex (F/M) | 29/30 | 11/11 | 9/12 | χ2=0.22 p=0.64 | 7/12 | 10/13 | χ2=0.19 p=0.66 |
14/7 | 10/8 | χ2=0.51 p=0.48 | χ2<0.01 p=1 | χ2=3.78 p=0.15 |
| Age | 30.37 (13.30) |
35.59 (12.91) |
29.36 (7.30) |
t=1.93 p=0.06 |
37.67 (14.16) |
29.32 (7.07) |
t=2.48 p=0.02 |
35.52 (13.40) |
30.98 (10.72) |
t=1.15 p=0.26 |
t=−1.19 p=0.23 | F=0.06 p=0.94 |
| QIDSBL | 13 (6–23) |
17 (8–22) |
U=327.50 p=0.02 |
16 (3–20) |
15 (6–20) |
U=194.0 p=0.53 |
14 (8–19) |
14 (7–19) |
U=195.50 p=0.86 |
KW=1.07 p=0.59 |
||
| QIDSFU | 10 (5–19) |
5 (1–7) |
U=38 p<0.01 |
11 (2–19) |
5 (1–9) |
U=25.50 p<0.01 |
10 (6–17) |
3.5 (1–7) |
U=4 p<0.01 |
KW=0.24 p=0.88 |
||
| HRSDBL | 22.50 (17–29) |
23 (16–34) |
U=269.50 p=0.35 |
21 (16–30) |
21 (16–26) |
U=207.50 p=0.78 |
21 (16–31) |
21.50 (17–28) |
U=224.50 p=0.32 |
KW=4.11 p=0.13 |
||
| HRSDFU | 13 (3–20) |
7 (2–14) |
U=5.00 p<0.01 |
12 (5–21) |
7 (2–16) |
U=88.50 p<0.01 |
13 (6–25) |
5 (3–16) |
U=33.50 p<0.01 |
KW<0.01 p=1 |
||
| Dysthymia | 12 | 7 | χ2=1.96 p=0.16 |
9 | 11 | χ2<0.01 p=0.98 |
7 | 8 | χ2=0.51 p=0.47 |
χ2=0.70 p=0.40 |
||
| Panic | 5 | 2 | χ2=1.37 p=0.24 |
3 | 1 | χ2=1.58 p=0.21 |
1 | 2 | χ2=0.55 p=0.46 |
χ2=1.70 p=0.19 |
||
| Agoraphobia | 4 | 6 | χ2=0.65 p=0.42 |
6 | 4 | χ2=1.15 p=0.28 |
4 | 2 | χ2=0.47 p=0.49 |
χ2=1.07 p=0.30 |
||
| Social phobia | 8 | 8 | χ2=0.01 p=0.92 |
6 | 11 | χ2=1.14 p=0.29 |
9 | 9 | χ2=0.20 p=0.65 |
χ2=0.69 p=0.41 |
||
| Specific phobia | 4 | 3 | χ2=0.12 p=0.73 |
3 | 5 | χ2=0.24 p=0.62 |
5 | 0 | χ2=4.92 p=0.03 |
χ2=0.58 p=0.47 |
||
| Generalized anxiety | 0 | 2 | χ2=2.20 p=0.14 |
1 | 0 | χ2=1.24 p=0.26 |
2 | 0 | χ2=1.81 p=0.18 |
χ2=0.46 p=0.50 |
||
Factors and comorbidities are reported as counts, parametric variables as mean (standard deviation), non-parametric variables as median (minimum-maximum). We also report results of statistical tests comparing NR and R within each treatment arm, comparing MDD and HC, assessing differences between treatment arms at baseline. Response was defined as 50% reduction of baseline QIDS. When defined based on 50% reduction of HRSD instead, remission rates were: escitalopram: 24/43, sertraline: 24/42, venlafaxine: 21/39.
Abbreviations: BL=baseline, F=female, FU=follow-up, HC=healthy controls, HRSD=Hamilton Rating Scale for Depression, KW=Kruskall-Wallis test, M=male, MDD=depressed patients, NR=non-responders, QIDS=Quick Inventory of Depressive Symptomatology scale, R=responders, t=independent samples t-test, U=Mann-Whitney U test, χ2=chi-square test, XR=extended release.